ASX:ANN

Stock Analysis Report

Executive Summary

Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, Caribbean, and North America.

Snowflake

Fundamentals

Flawless balance sheet average dividend payer.


Similar Companies

Share Price & News

How has Ansell's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.7%

ASX:ANN

-3.5%

AU Medical Equipment

0.5%

AU Market


1 Year Return

11.3%

ASX:ANN

11.8%

AU Medical Equipment

6.3%

AU Market

ANN underperformed the Medical Equipment industry which returned 12.7% over the past year.

ANN outperformed the Market in Australia which returned 6.3% over the past year.


Share holder returns

ANNIndustryMarket
7 Day0.7%-3.5%0.5%
30 Day5.9%5.0%4.6%
90 Day6.7%5.6%2.1%
1 Year14.2%11.3%13.0%11.8%12.3%6.3%
3 Year36.9%26.8%44.3%38.5%41.4%22.4%
5 Year63.7%43.4%144.9%126.1%49.4%16.6%

Price Volatility Vs. Market

How volatile is Ansell's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ansell undervalued based on future cash flows and its price relative to the stock market?

23.15x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Ansell's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Ansell's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Ansell is good value based on earnings compared to the AU Medical Equipment industry average.

Ansell is overvalued based on earnings compared to the Australia market.


Price Based on Expected Growth

Ansell is poor value based on expected growth next year.


Price Based on Value of Assets

Ansell is good value based on assets compared to the AU Medical Equipment industry average.


Next Steps

Future Growth

How is Ansell expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

12.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Ansell's revenue is expected to grow by 3.6% yearly, however this is not considered high growth (20% yearly).

Ansell's earnings are expected to grow by 12.9% yearly, however this is not considered high growth (20% yearly).

Ansell's revenue growth is expected to exceed the Australia market average.

Ansell's earnings growth is expected to exceed the Australia market average.

Ansell's earnings growth is expected to exceed the low risk savings rate of 2.3%.


Earnings per Share Growth Estimates


Future Return on Equity

Ansell is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Ansell performed over the past 5 years?

3.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Ansell's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.

Ansell's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Ansell's 1-year earnings growth is negative, it can't be compared to the AU Medical Equipment industry average.


Return on Equity

Ansell has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Ansell used its assets less efficiently than the AU Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Ansell's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Ansell's financial position?


Financial Position Analysis

Ansell is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Ansell's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Ansell's level of debt (38.7%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (64.4% vs 38.7% today).

Debt is well covered by operating cash flow (34.6%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 18.4x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.8x debt.


Next Steps

Dividend

What is Ansell's current dividend yield, its reliability and sustainability?

2.79%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Ansell's pays a higher dividend yield than the bottom 25% of dividend payers in Australia (2.44%).

Ansell's dividend is below the markets top 25% of dividend payers in Australia (5.52%).

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are covered by earnings (1.8x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (2.3x coverage).


Next Steps

Management

What is the CEO of Ansell's salary, the management and board of directors tenure and is there insider trading?

0.4yrs

Average management tenure


CEO

Magnus Nicolin (62yo)

9.5yrs

Tenure

US$5,306,544

Compensation

Mr. Magnus R. Nicolin, BA (Stockholm), MBA (Wharton), has been the Chief Executive Officer and Managing Director of Ansell Limited since March 1, 2010. Mr. Nicolin served as the President of Europe, Middle ...


CEO Compensation Analysis

Magnus's remuneration is higher than average for companies of similar size in Australia.

Magnus's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

0.4yrs

Average Tenure

The average tenure for the Ansell management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.8yrs

Average Tenure

62yo

Average Age

The tenure for the Ansell board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$609,01925 Jul 19
BlackRock, Inc.
EntityCompany
Shares1,976,406
Max PriceUS$27.41
SellUS$64,10925 Jul 19
BlackRock, Inc.
EntityCompany
Shares666,526
Max PriceUS$27.32
SellUS$68,93908 Apr 19
BlackRock, Inc.
EntityCompany
Shares1,438,025
Max PriceUS$29.00
BuyUS$236,62208 Apr 19
BlackRock, Inc.
EntityCompany
Shares2,252,573
Max PriceUS$29.03
SellUS$48,691,20121 Feb 19
Vinva Investment Management
EntityCompany
Shares2,123,533
Max PriceUS$22.93
BuyUS$80,865,27321 Feb 19
Vinva Investment Management
EntityCompany
Shares3,326,730
Max PriceUS$24.31
SellUS$29,710,43431 Jan 19
Nikko Asset Management Co., Ltd.
EntityCompany
Shares1,270,434
Max PriceUS$23.39
BuyUS$116,22331 Jan 19
Nikko Asset Management Co., Ltd.
EntityCompany
Shares5,333
Max PriceUS$21.79
BuyUS$3,29607 Jan 19
Christina Stercken
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares148
Max PriceUS$22.27
BuyUS$36,958,97821 Dec 18
Nikko Asset Management Co., Ltd.
EntityCompany
Shares1,550,895
Max PriceUS$25.02
BuyUS$11,56507 Nov 18
Christina Stercken
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares500
Max PriceUS$23.13
BuyUS$7,339,43230 Oct 18
The Vanguard Group, Inc.
EntityCompany
Shares251,502
Max PriceUS$29.56
SellUS$1,232,20730 Oct 18
The Vanguard Group, Inc.
EntityCompany
Shares43,878
Max PriceUS$29.04
SellUS$3,512,73202 Oct 18
Vinva Investment Management
EntityCompany
Shares138,620
Max PriceUS$25.34
BuyUS$93,54402 Oct 18
Vinva Investment Management
EntityCompany
Shares3,671
Max PriceUS$25.48
SellUS$7,817,57224 Sep 18
Vinva Investment Management
EntityCompany
Shares285,455
Max PriceUS$27.39
BuyUS$10,644,26924 Sep 18
Vinva Investment Management
EntityCompany
Shares419,037
Max PriceUS$25.40

Ownership Breakdown


Management Team

  • Magnus Nicolin (62yo)

    MD, CEO & Executive Director

    • Tenure: 9.5yrs
    • Compensation: US$5.31m
  • Neil Salmon (50yo)

    President of Industrial GBU

    • Tenure: 0.4yrs
    • Compensation: US$2.12m
  • Peter Dobbelsteijn

    Senior Vice President of Global Supply Chain

    • Tenure: 9.1yrs
    • Compensation: US$1.02m
  • Giri Peddinti

    Senior VP & Global Chief Information Officer

    • Tenure: 7.7yrs
  • Darryl Nazareth

    President of Healthcare GBU

    • Tenure: 0.4yrs
    • Compensation: US$517.38k
  • Mike Gilleece

    Senior VP & Corporate General Counsel

    • Tenure: 2.2yrs
  • Jocelyn Petersen

    Vice President of Global FP&A

    • Tenure: 0yrs
  • Zubair Javeed

    Chief Financial Officer

    • Tenure: 0.4yrs
    • Compensation: US$345.85k
  • John Marsden

    Senior VP of Global Operations and R&D

    • Tenure: 0.4yrs
  • Amanda Manzoni

    Chief Human Resources Officer

    • Tenure: 0.3yrs

Board Members

  • Marissa Peterson (57yo)

    Independent Non-Executive Director

    • Tenure: 13.1yrs
    • Compensation: US$173.50k
  • Magnus Nicolin (62yo)

    MD, CEO & Executive Director

    • Tenure: 9.5yrs
    • Compensation: US$5.31m
  • John Bevan (62yo)

    Deputy Chairman

    • Tenure: 2.6yrs
    • Compensation: US$175.00k
  • William Day (69yo)

    Independent Non-Executive Director

    • Tenure: 12.1yrs
    • Compensation: US$174.50k
  • Glenn Lawrence Barnes (72yo)

    Chairman

    • Tenure: 6.9yrs
    • Compensation: US$335.00k
  • Bill Reilly (67yo)

    Non-Executive Director

    • Tenure: 1.9yrs
    • Compensation: US$151.50k
  • Christina Stercken (61yo)

    Independent Non-Executive Director

    • Tenure: 1.9yrs
    • Compensation: US$155.50k
  • Leslie Desjardins (59yo)

    Independent Non-Executive Director

    • Tenure: 3.8yrs
    • Compensation: US$167.50k
  • Christine Yan (53yo)

    Independent Non-Executive Director

    • Tenure: 0.4yrs
    • Compensation: US$38.88k

Company Information

Ansell Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ansell Limited
  • Ticker: ANN
  • Exchange: ASX
  • Founded: 1888
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$3.632b
  • Shares outstanding: 131.71m
  • Website: https://www.ansell.com

Number of Employees


Location

  • Ansell Limited
  • 678 Victoria Street
  • Level 3
  • Richmond
  • Victoria
  • 3121
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ANSL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1992
ANNASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJan 1992
PD1ADB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992
ANNCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJan 1992
ANSL.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDOct 2007

Biography

Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, Caribbean, and North America. It operates through two segments,  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 10:34
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.